ASH Annual Meeting & Exposition CAR-T | Conference

Deepu Madduri, MD, on Next Steps for the CARTITUDE-1 Trial
January 18, 2021

The phase 1b/2 trial evaluated a single, low-dose infusion of ciltacabtagene autoleucel (cilta-cel; JNJ-68284528) in heavily pretreated patients with relapsed or refractory multiple myeloma.

Deepu Madduri, MD, on the Implications of the Phase 1b/2 CARTITUDE-1 Trial Results
January 14, 2021

Based on findings from the trial of ciltacabtagene autoleucel, further investigation of the therapy in other populations of patients with multiple myeloma is already underway.

Deepu Madduri, MD, on the Design of the Phase 1b/2 CARTITUDE-1 Trial
January 12, 2021

The goal of the CARTITUDE-1 study was to evaluate the use of ciltacabtagene autoleucel (cilta-cel; JNJ-68284528) chimeric antigen receptor T-cell therapy in heavily pretreated patients with relapsed or refractory multiple myeloma.